ReviewKidney medicine2025
The Endothelial Glycocalyx: The First Line of Defense in the Prevention and Treatment of Kidney Diseases.
Review in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- Endothelial Glycocalyx in Kidney Transplantation: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- The Effect of Intravenous Thrombolysis and Mechanical Thrombectomy on Change in the Concentrations of Interleukin-18 and Degradation Products of the Endothelial Glycocalyx in Patients with Acute Ischemic Stroke.Life (Basel, Switzerland) · 2026Article
- Serum syndecan-1 correlates with coronary artery calcification severity and intradialytic hypotension in elderly hemodialysis patients.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endothelial glycocalyx (EG) is widely located on the surface of endothelial cell membrane. It serves as an important component of the endothelial cell barrier and plays a crucial role in maintaining charge balance within the cell. The shedding, excessive thickening and deposition of the EG located on the surface of endothelial cells within the renal capillary network is widely observed in acute kidney injury and chronic kidney disease. Based on recent research advancements, this article focuses on how the EG in the renal microvasculature participates in pathological processes such as renal tubulointerstitial fibrosis, cross-talk between endothelial cells and epithelial cells, and immune system dysregulation. Preserving and restoring the integrity of the EG in the renal microvasculature has emerged as an innovative strategy for the early prevention and treatment of kidney diseases. This includes supplementation of EG components and inhibition of EG shedding ingredients to prevent EG damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.